Lifeboat Foundation

Researchers have uncovered that proteins use a common chemical label as a shield to protect them from degradation, which in turn affects motility and aging. Proteins are key to all processes in our cells and understanding their functions and regulation is of major importance.

“For many years, we have known that nearly all human proteins are modified by a specific chemical group, but its functional impact has remained undefined,” says professor Thomas Arnesen at the Department of Biomedicine, University of Bergen.

Aging is a natural process that affects all living organisms, prompting gradual changes in their behavior and abilities. Past studies have highlighted several physiological factors that can contribute to aging, including the body’s immune responses, an imbalance between the production of reactive oxygen (i.e., free radicals) and antioxidants, and sleep disturbances.

While the link between aging and these different factors is well-document, the connection between them is still poorly understood. Researchers at Washington University in St. Louis recently identified an immune molecule that could play a key role in modulating the process of aging and the duration living organism’s lifespan.

Their paper, published in Neuron, was inspired by two independent research efforts at the university.

Japanese scientists have developed a new type of plastic that’s strong at room temperature, but can be easily broken down on demand into its base components. In seawater, it starts to break down into food for marine life, and just to top it off, it can self-heal and remember past shapes.

Plastic is everywhere in our modern world, for better or worse. Its toughness makes it an extremely useful material for everything from household items to vehicle parts, but that same toughness makes it hard to break down for recycling or disposal.

In the new study, scientists at the University of Tokyo developed a new plastic material that can be broken down more easily, either in recycling plants or in nature. It’s based on a class of plastic called an epoxy resin vitrimer, which are strong at room temperature but can be reshaped and molded with a bit of added heat. Normally, vitrimers are brittle, but the team improved the recipe by adding a molecule called polyrotaxane.

More than a decade ago, the co-founder of Google’s DeepMind artificial intelligence lab predicted that by 2028, AI will have a half-and-half shot of being about as smart as humans — and now, he’s holding firm on that forecast.

In an interview with tech podcaster Dwarkesh Patel, DeepMind co-founder Shane Legg said that he still thinks that researchers have a 50–50 chance of achieving artificial general intelligence (AGI), a stance he publicly announced at the very end of 2011 on his blog.

It’s a notable prediction considering the exponentially growing interest in the space. OpenAI CEO Sam Altman has long advocated for an AGI, a hypothetical agent that is capable of accomplishing intellectual tasks as well as a human, that can be of benefit to all. But whether we’ll ever be able to get to that point — let alone agree on one definition of AGI — remains to be seen.

Musk cofounded OpenAI—the parent company of the viral chatbot ChatGPT—in 2015 alongside Altman and others. But when Musk proposed that he take control of the startup to catch up with tech giants like Google, Altman and the other cofounders rejected the proposal. Musk walked away in February 2018 and changed his mind about a “massive planned donation.”

Now Musk’s new company, xAI, is on a mission to create an AGI, or artificial general intelligence, that can “understand the universe,” the billionaire said in a nearly two-hour-long Twitter Spaces talk on Friday. An AGI is a theoretical type of A.I. with human-like cognitive abilities and is expected to take at least another decade to develop.

Musk’s new company debuted only days after OpenAI announced in a July 5 blog post that it was forming a team to create its own superintelligent A.I. Musk said xAI is “definitely in competition” with OpenAI.

Scientists from the University of California Davis (UC Davis) Comprehensive Cancer Center have recently published in Cell Death and Disease, identifying a critical protein that causes cells to die. The protein is described as an epitope, which is a section of the protein that is recognized by the immune system to activate a response. This epitope was distinctly found on the CD95 receptor, known to trigger programmed cell death. The report demonstrates a new mechanism to trigger cell death and provide further insight into improved disease treatments.

CD95 receptors, also referred to a “Fas”, are cell death receptors which are present on cell membranes. Once Fas is activated, it generates a signaling cascade which elicits cell death. The mechanism by which cells self-destruct has been an important research topic. By understanding cell death, scientists can generate better therapies for different diseases, including cancer.

Currently, cancer is treated by surgery, chemotherapy, or radiotherapy. Despite initial success, these treatments are unable to fully eradicate tumor cells. Immunotherapy is a new approach to target cancer. Immunotherapy refers to therapeutics modulating the immune system to elicit an effective immune response. This is a more indirect approach compared to lysing tumors with a chemical. One specific immunotherapy referred to as chimeric antigen receptor (CAR) T-cell therapy is a treatment in which T cells, or cytotoxic immune cells, are engineered to lyse tumor cells. Unfortunately, CAR T-cell therapy is limited due to the tumor’s ability to prevent T cell activation.

Two people born on the same day can age very differently.

Biological age diagnostics help pinpoint the rate a person ages regardless of the amount of time they have spent on earth. This could provide earlier detection of disease for personalised preventative strategies.

Our FREE comprehensive market intelligence report demonstrates how biological age diagnostics are radically transforming how we see and tackle aging.

Take courses developed and taught by the same tenured & tenure-track faculty as on campus.

After enduring intense treatments and a 10-hour surgery as a high school junior to treat a rare form of cancer, Callan currently has no evidence of disease and is a student of fine arts at the University of Texas. Read how his family is helping others diagnosed with this rare cancer.

In October 2021, Callan began experiencing a mysterious pain in his neck. A talented artist and a good student, Callan had been looking forward to his junior year of high school. After also developing a cough, he was diagnosed with walking pneumonia, but later imaging showed a large tumor in his chest.

Multiple doctors told Callan the tumor, diagnosed as synovial sarcoma, was inoperable. Synovial sarcoma is often deadly without surgery, but his family eventually found a team willing to operate. Callan currently has no evidence of disease.

Continue reading “Callan — Childhood Cancer Survivor” »